The "Global Access" Mandate: How 2026 is Breaking the "Wealth Barrier" to Recovery.
As we move through 2026, the industry is undergoing a quiet "Global Equity Revolution." This year, the Opioid Use Disorder Market has achieved a "Low-Cost Biosimilar" milestone, with the first wave of generic long-acting buprenorphine hitting markets in India and Southeast Asia. This is proving essential for ensuring that the global south—which is seeing a 12% rise in opioid...
0 Commentarii 0 Distribuiri 0 previzualizare